Study of the Impact on Survival of a Paradigm Shift in the Therapeutic Strategy of Patients With Advanced Ovarian Cancer

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06907771

Acronym

PACO

Enrollment

130

Registered

2025-04-02

Start date

2024-04-22

Completion date

2025-12-22

Last updated

2025-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Cancer

Keywords

Ovarian cancer

Brief summary

Ovarian cancer is the 8th leading cause of cancer-related death in women. Its prognosis is poor, with diagnosis often made at an advanced stage. Patient management has evolved in recent years with more radical surgeries and the introduction of maintenance treatment following neoadjuvant chemotherapy.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Inclusion criteria

* Adult patient (≥18 years old) * Operated on at the HUS between January 1, 2010 and December 31, 2022 * Having undergone primary or interval cytoreductive surgery * Suffering from stage FIGO IIIC or IV high-grade serous carcinoma of ovarian origin

Exclusion criteria

* Patiente ayant exprimé son opposition à la réutilisation de ses données à des fins de recherches scientifiques. * Autres types histologiques de cancer de l'ovaire * Stades de la maladie FIGO I, II, IIIA et IIIC * Chirurgie de clôture.

Design outcomes

Primary

Measure	Time frame
Study of progression-free survival at 36 months	At 36 months

Countries

France

Contacts

Primary ContactLise LECOINTRE, MD

lise.lecointre@chu-strasbourg.fr33 3 88 12 75 10

Outcome results